REBEL Cast
REBEL Cast
Salim R. Rezaie, MD
REBEL Core Cast 125.0 – Hyperkalemia
7 minutes Posted Jun 26, 2024 at 3:00 pm.
–330. PMID: 18235147
–872. PMID: 2266671
0:00
7:56
Download MP3
Show notes
Take Home Points
Always obtain an EKG in patients with ESRD upon presentation
Always obtain an EKG in patients with hyperkalemia as pseudohyperkalemia is the number one cause
If the patient with hyperkalemia is unstable or has significant EKG changes (wide QRS, sine wave) rapidly administer calcium salts
In patients who are anuric, early mobilization of dialysis resources is critical
REBEL Core Cast 125.0 – Hyperkalemia
Click here for Direct Download of the Podcast.
Definition: A serum potassium level > 5.5 mmol/L
Epidemiology
Common electrolyte disorder
10% of hospitalized patients (Elliott 2010)
Causes
Pseudohyperkalemia: extravascular hemolysis
Renal failure (potassium is primarily eliminated by the kidneys)
Acidosis
Massive cell death (tumor lysis syndrome, rhabdomyolysis, burns, crush injuries, hemolysis)
Drugs: ACEI, ARBs, Spironalactone, NSAIDs, Succinycholine
Clinical Manifestations
Mild hyperkalemia often asymptomatic
Cardiac Effects
Increased potassium raises the resting membrane potential of cardiac myocytes
Slows ventricular conduction
Decreases length of action potential
Increases cardiac myocyte excitability
Cardiac effects can manifest in lethal dysrhythmias
Neuromuscular Effects
Paresthesias
Weakness
Flaccid paralysis
Depressed or absent deep tendon reflexes
Diagnosis
Suspect hyperkalemia in ALL patients with renal impairment, especially end-stage renal disease (ESRD)
Serum potassium
Can be artificially elevated by extravascular hemolysis
Blood gas results may differ from standard metabolic panels by up to 0.5mmol/L
12-Lead EKG
Screening test that can rapidly detect severe cardiac manifestations of hyperkalemia
A normal EKG with a significant serum potassium elevation should raise concerns for spurious results (extravascular hemolysis)
Sensitivity of EKG to detect hyperkalemia is poor (Wrenn 1991, Aslam 2002, Montague 2008)
Classic EKG findings
PR prolongation
Peaked T waves
Loss of P waves
Widening of QRS complex
Sine wave
Ventricular Fibrillation
Asystole
Note: Hyperkalemia can present with a number of “non-classic” EKG findings including AV blocks and sinus bradycardia (Mattu 2000)
Note: Hyperkalemic EKG changes do not necessarily occur in order (i.e. patients can jump from peaked T waves to sine wave)
Management
Basics: ABCs, IV, O2, Cardiac Monitor and, 12-lead EKG
Identify + treat underlying cause of hyperkalemia (i.e. rhabdomyolysis -> hydration)
Remove inciting factors (i.e. stop ACEI, NSAIDs etc)
Asymptomatic Patients without EKG Changes
Eliminate potassium from the body
Binding agents (SPS, Sodium zirconium cyclosilicate etc)
Enhance renal elimination
Intravenous hydration if volume depleted
Consider potassium wasting loop diuretics (i.e. furosemide)
Dialysis for anuric patients (i.e. ESRD)
Symptomatic Patients or Significant EKG Changes
Stabilize cardiac myocytes with calcium salts
Mechanism: Recreates the electrical gradient leading to rapid reversal of cardiac effects and rapid stabilization
Two Options: CaGluconate, CaCl2
No difference in time to onset (1st pass metabolism is a myth)
Dose: 1 ampule CaCl2 (270 mg Ca2+) = 3 ampules CaGluconate (90 mg Ca2+/ampule)
Onset of action: seconds to minutes
Duration: 20-30 minutes
Shift potassium into intracellular space (temporary)
Insulin (Moussavi 2021)
Mechanism: Activation of the Na-K-ATPase
Dose: 5-10 units IV
Onset of Action: < 15 min
Effect: Lowers potassium by about 0.6 mmol
Duration of action: 30-60 min
Give with dextrose (0.5 – 1 g/kg) unless hyperglycemia present
Caution: Duration of action of insulin may outlast administered dextrose. Be vigilant for hypoglycemia
Beta-adrenoreceptor agonists (i.e. albuterol)
Mechanism: Activation of beta receptors
Dose: 10-20 mg inhaled (4-8 standard ampules)
Onset of Action: < 15 min
Effect: Lowers potassium by about 0.6 mmol
Duration of action: 30-60 min
Additive effect with insulin (Allon 1990)
Note: Unlikely to have effect in patients taking beta-adrenoreceptor blocker medications
Sodium Bicarbonate (NaHCO3)
Evidence for the efficacy of NaHCO3 to lower serum potassium is scant and contradictory (Elliott 2010, Weisberg 2008)
Eliminate potassium from the body (see above)
Asymptomatic Patients with Minor EKG Changes
Minimal recommendations on managing this clinical entity
Eliminate potassium from the body (see above)
Consider calcium salt administration: patients can rapidly progress through EKG changes and calcium administration may prevent this from occurring. However, the effects of calcium are temporary and offer no long-term protection
Consider medications to shift potassium intracellularly while waiting for elimination
Take Home Points
Always obtain an EKG in patients with ESRD upon presentation
Always obtain an EKG in patients with hyperkalemia as pseudohyperkalemia is the number one cause
If the patient with hyperkalemia is unstable or has significant EKG changes (wide QRS, sine wave) rapidly administer calcium salts
In patients who are anuric, early mobilization of dialysis resources is critical
References
Elliott MJ et al. Management of patients with acute hyperkalemia. CMAJ 2010; 182(15): 1631-5. PMID: 20855477
Wrenn K et al. The ability of physicians to predict hyperkalemia from the ECG. Ann Emerg Med 1991; 20(11): 1229-32. PMID: 1952310
Aslam S et al. Electrocardiography is unreliable in detecting potentially lethal hyperkalaemia in hemodialysis patients. Nephrol Dial Transplant 2002; 17: 1639-42. PMID: 12198216
Montague BT et al. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol 2008;
3:324–330. PMID: 18235147
Mattu A et al. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med 2000; 18: 721-9. PMID: 11043630
Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990;
38:869–872. PMID: 2266671
Weisberg LS. Management of hyperkalemia. Crit Care Med 2008; 36: 3246-51. PMID: 18936701
Moussavi K et al. Reduced alternative insulin dosing in hyperkalemia: a meta-analysis of effects on hypoglycemia and potassium reduction. Pharmacotherapy 2021; 41(7): 598-607. PMID: 33993515
Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter/X: @srrezaie)
The post REBEL Core Cast 125.0 – Hyperkalemia appeared first on REBEL EM - Emergency Medicine Blog.